• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于鉴定强效和选择性S1P受体激动剂的非比对3D-QSAR研究及分子动力学模拟

Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P receptor agonists.

作者信息

Alizadeh Ali Akbar, Jafari Behzad, Dastmalchi Siavoush

机构信息

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medicinal Chemistry, School of Pharmacy, Urmia University of Medical Sciences, Iran.

出版信息

J Mol Graph Model. 2020 Jan;94:107459. doi: 10.1016/j.jmgm.2019.107459. Epub 2019 Sep 29.

DOI:10.1016/j.jmgm.2019.107459
PMID:31589999
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7110456/
Abstract

Sphingosine 1-phosphate type 1 (S1P) receptors are expressed on lymphocytes and regulate immune cells trafficking. Sphingosine 1-phosphate and its analogues cause internalization and degradation of S1P receptors, preventing the auto reactivity of immune cells in the target tissues. It has been shown that S1P receptor agonists such as fingolimod can be suitable candidates for treatment of autoimmune diseases. The current study aimed to generate GRIND-based 3D-QSAR predictive models for agonistic activities of 2-imino-thiazolidin-4-one derivatives on S1P to be used in virtual screening of chemical libraries. The developed model for the S1P receptor agonists showed appropriate power of predictivity in internal (r 0.93 and SDEC 0.18) and external (r 0.75 and MAE (95% data), 0.28) validations. The generated model revealed the importance of variables DRY-N1 and DRY-O in the potency and selectivity of these compounds towards S1P receptor. To propose potential chemical entities with S1P agonistic activity, PubChem chemicals database was searched and the selected compounds were virtually tested for S1P receptor agonistic activity using the generated models, which resulted in four potential compounds with high potency and selectivity towards S1P receptor. Moreover, the affinities of the identified compounds towards S1P receptor were evaluated using molecular dynamics simulations. The results indicated that the binding energies of the compounds were in the range of -39.31 to -46.18 and -3.20 to -9.75 kcal mol, calculated by MM-GBSA and MM-PBSA algorithms, respectively. The findings in the current work may be useful for the identification of potent and selective S1P receptor agonists with potential use in diseases such as multiple sclerosis.

摘要

1-磷酸鞘氨醇1型(S1P)受体在淋巴细胞上表达,并调节免疫细胞的迁移。1-磷酸鞘氨醇及其类似物会导致S1P受体的内化和降解,从而防止免疫细胞在靶组织中发生自身反应。研究表明,像芬戈莫德这样的S1P受体激动剂可能是治疗自身免疫性疾病的合适候选药物。当前的研究旨在生成基于GRIND的三维定量构效关系(3D-QSAR)预测模型,用于预测2-亚氨基噻唑烷-4-酮衍生物对S1P的激动活性,以用于化学文库的虚拟筛选。所开发的S1P受体激动剂模型在内部验证(r = 0.93,标准偏差估计值(SDEC)= 0.18)和外部验证(r = 0.75,平均绝对误差(MAE,95%数据)= 0.28)中显示出适当的预测能力。生成的模型揭示了变量DRY-N1和DRY-O在这些化合物对S1P受体的效力和选择性方面的重要性。为了提出具有S1P激动活性的潜在化学实体,搜索了PubChem化学数据库,并使用生成的模型对所选化合物进行了S1P受体激动活性的虚拟测试,结果得到了四种对S1P受体具有高效力和选择性的潜在化合物。此外,使用分子动力学模拟评估了所鉴定化合物对S1P受体的亲和力。结果表明,分别通过MM-GBSA和MM-PBSA算法计算,这些化合物的结合能在-39.31至-46.18千卡/摩尔和-3.20至-9.75千卡/摩尔范围内。当前工作的研究结果可能有助于识别具有高效力和选择性的S1P受体激动剂,这些激动剂在诸如多发性硬化症等疾病中可能具有潜在用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/a2680efd1aa8/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5016be542ce2/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/ad0a25a6fe0b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/cb0b263cca10/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/d0a476b38ecd/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/9aa35c802ad8/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/2ad0caa81b90/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/e3a1d9a9fc14/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5f874a3502f7/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/d797ac5d9b4e/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5cc4607324c6/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/a2680efd1aa8/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5016be542ce2/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/ad0a25a6fe0b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/cb0b263cca10/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/d0a476b38ecd/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/9aa35c802ad8/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/2ad0caa81b90/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/e3a1d9a9fc14/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5f874a3502f7/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/d797ac5d9b4e/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/5cc4607324c6/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3710/7110456/a2680efd1aa8/gr10_lrg.jpg

相似文献

1
Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P receptor agonists.用于鉴定强效和选择性S1P受体激动剂的非比对3D-QSAR研究及分子动力学模拟
J Mol Graph Model. 2020 Jan;94:107459. doi: 10.1016/j.jmgm.2019.107459. Epub 2019 Sep 29.
2
Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P) Receptor Agonists.丝氨酰内酰胺衍生物的合成与评价作为鞘氨醇-1-磷酸-1(S1P)受体激动剂。
Molecules. 2022 Apr 28;27(9):2818. doi: 10.3390/molecules27092818.
3
Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches.利用计算机辅助药物设计方法进行药物重新利用,以鉴定具有治疗多发性硬化症潜在应用价值的S1P1激动剂。
Adv Pharm Bull. 2023 Jan;13(1):113-122. doi: 10.34172/apb.2023.012. Epub 2022 Jan 3.
4
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).鞘氨醇 1-磷酸受体 1 激动剂:专利审查(2013-2015)。
Expert Opin Ther Pat. 2016;26(4):455-70. doi: 10.1517/13543776.2016.1157165. Epub 2016 Mar 15.
5
Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.鞘氨醇-1-磷酸(S1P)通过 S1P 裂解酶依赖性受体再循环,显示出持续的 S1P1 受体激动作用和信号转导。
Cell Signal. 2014 Jul;26(7):1576-88. doi: 10.1016/j.cellsig.2014.03.029. Epub 2014 Apr 2.
6
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P) Agonists and Future Perspectives.鞘氨醇-1-磷酸途径生物学的调节剂:鞘氨醇-1-磷酸受体1(S1P)激动剂的最新进展及未来展望
J Med Chem. 2017 Jul 13;60(13):5267-5289. doi: 10.1021/acs.jmedchem.6b01575. Epub 2017 Mar 30.
7
3D-QSAR studies on thiazolidin-4-one S1P₁receptor agonists by CoMFA and CoMSIA.噻唑烷-4-酮 S1P₁受体激动剂的 3D-QSAR 研究:CoMFA 和 CoMSIA 分析。
Int J Mol Sci. 2011;12(10):6502-16. doi: 10.3390/ijms12106502. Epub 2011 Sep 28.
8
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.免疫抑制和抗血管生成的1-磷酸鞘氨醇受体-1激动剂可诱导该受体的泛素化和蛋白酶体降解。
J Biol Chem. 2007 Mar 23;282(12):9082-9. doi: 10.1074/jbc.M610318200. Epub 2007 Jan 21.
9
PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.过氧化物酶体增殖物激活受体γ(PPARγ)激动剂上调1-磷酸鞘氨醇(S1P)受体1的表达,进而减少S1P诱导的肾系膜细胞内钙离子浓度([Ca(2+)]i)升高。
Biochim Biophys Acta. 2013 Nov;1831(11):1634-43. doi: 10.1016/j.bbalip.2013.07.011. Epub 2013 Jul 30.
10
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1).鞘氨醇-1-磷酸1(S1P1)强效和选择性吡啶基异恶唑类激动剂的鉴定与合成。
Bioorg Med Chem Lett. 2016 May 15;26(10):2470-2474. doi: 10.1016/j.bmcl.2016.03.105. Epub 2016 Apr 1.

引用本文的文献

1
Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches.利用计算机辅助药物设计方法进行药物重新利用,以鉴定具有治疗多发性硬化症潜在应用价值的S1P1激动剂。
Adv Pharm Bull. 2023 Jan;13(1):113-122. doi: 10.34172/apb.2023.012. Epub 2022 Jan 3.
2
Virtual Screening-Based Drug Development for the Treatment of Nervous System Diseases.基于虚拟筛选的神经系统疾病治疗药物研发。
Curr Neuropharmacol. 2023;21(12):2447-2464. doi: 10.2174/1570159X20666220830105350.
3
3D-QSAR Studies of 1,2,4-Oxadiazole Derivatives as Sortase A Inhibitors.

本文引用的文献

1
Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects in vitro and in vivo by S1P receptor 4-mediated suppression of 5-lipoxygenase activity.鞘氨醇-1-磷酸(S1P)通过 S1P 受体 4 介导的 5-脂氧合酶活性抑制,在体外和体内产生强大的抗炎作用。
FASEB J. 2019 Feb;33(2):1711-1726. doi: 10.1096/fj.201800221R. Epub 2018 Sep 6.
2
An Alignment-Independent 3D-QSAR Study of FGFR2 Tyrosine Kinase Inhibitors.成纤维细胞生长因子受体2(FGFR2)酪氨酸激酶抑制剂的非比对三维定量构效关系研究
Adv Pharm Bull. 2017 Sep;7(3):409-418. doi: 10.15171/apb.2017.049. Epub 2017 Sep 25.
3
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
3D-QSAR 研究 1,2,4-恶二唑衍生物作为 sortase A 抑制剂。
Biomed Res Int. 2021 Dec 6;2021:6380336. doi: 10.1155/2021/6380336. eCollection 2021.
4
Identification of Novel Mutations in DOF 4.2 Coding Gene.DOF 4.2编码基因中新突变的鉴定
Adv Pharm Bull. 2021 May;11(3):557-563. doi: 10.34172/apb.2021.064. Epub 2020 May 9.
奥扎莫德(RPC1063)是一种强效的1-磷酸鞘氨醇受体-1(S1P1)和受体-5(S1P5)激动剂,具有改善自身免疫性疾病的活性。
Br J Pharmacol. 2016 Jun;173(11):1778-92. doi: 10.1111/bph.13476. Epub 2016 Apr 28.
4
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.波尼莫德,一种选择性鞘氨醇-1-磷酸受体调节剂:一种治疗多发性硬化症和其他免疫介导疾病的潜在药物。
Ther Adv Chronic Dis. 2016 Jan;7(1):18-33. doi: 10.1177/2040622315617354.
5
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor.新型三环吲哚类化合物作为鞘氨醇-1-磷酸受体(S1P1受体)有效调节剂的设计与合成
Bioorg Med Chem Lett. 2015 Feb 1;25(3):659-63. doi: 10.1016/j.bmcl.2014.11.089. Epub 2014 Dec 9.
6
Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.芬戈莫德:在复发缓解型多发性硬化中的应用综述。
Drugs. 2014 Aug;74(12):1411-33. doi: 10.1007/s40265-014-0264-y.
7
Lipid14: The Amber Lipid Force Field.Lipid14:琥珀色脂质力场。
J Chem Theory Comput. 2014 Feb 11;10(2):865-879. doi: 10.1021/ct4010307. Epub 2014 Jan 30.
8
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.作为 S1P₁ 激动剂的融合三环吲哚,在自身免疫疾病的动物模型中具有强大的疗效。
Bioorg Med Chem Lett. 2012 Jul 1;22(13):4404-9. doi: 10.1016/j.bmcl.2012.04.129. Epub 2012 May 7.
9
Crystal structure of a lipid G protein-coupled receptor.脂质 G 蛋白偶联受体的晶体结构。
Science. 2012 Feb 17;335(6070):851-5. doi: 10.1126/science.1215904.
10
An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors.两种基于 MIF 的工具(Volsurf+ 和 Pentacle)在二元 QSAR 中的应用:以与 palinurin 相关的非 ATP 竞争性糖原合酶激酶 3β(GSK-3β)抑制剂数据集为例。
Eur J Med Chem. 2011 Mar;46(3):860-9. doi: 10.1016/j.ejmech.2010.12.024. Epub 2011 Jan 9.